GENENTECH

📅 Upcoming

🕒 Recent(90d)

News

• Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
  After former Legend Biotech CEO Ying Huang, Ph.D., left the company suddenly in July, Legend has found its permanent CEO, poaching Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its nex…
  fiercebiotech · 2d ago
• Roche, Dualitas team up to find bispecific drugs for immune diseases
  Through a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments.
  biopharma_dive · 2d ago
• Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive
  Roche is paying Dualitas Therapeutics $36.5 million upfront to screen over 300,000 novel bispecific combinations in search of new treatments for immunology and inflammation diseases.
  fiercebiotech · 2d ago
• Sionna says good-bye to 46% of staffers, including exec
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 3d ago
• 5 drugmakers chasing Merck and Moderna in the cancer vaccine race
  Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…
  biospace · 5d ago
• mRNA cancer vaccines’ biggest barriers to market
  Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
  biopharma_dive · 8d ago
• Chutes & Ladders—Longtime Takeda R&D chief to depart next June
  Takeda President of Research and Development Andy Plump, M.D., Ph.D., is leaving the company in June after twelve years in the position.
  fiercebiotech · 9d ago
• STAT+: Inhibrx claims first win for long-sought immunotherapy target
  “Pushing this is like a rock up a hill, because there’s been so much failure in the space,” said Inhibrx CEO Mark Lappe.
  stat · 11d ago
• Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?
  The announcement from Merck & Co. and Moderna last month that their mRNA cancer vaccine had successfully lengthened patient survival in a phase 3 study affirmed the two companies' years of hard wor…
  fiercebiotech · 18d ago
• Roche finds another oncology gem in Asia with $1.5B B cell disease partnership
  Roche has tapped Simcere Zaiming for a new T cell engager that could have broad application in B cell–mediated diseases including lymphoma and autoimmune conditions.
  biospace · 18d ago